Grade 3 or 4 AEs associated with bevacizumab treatment were reported in 6 patients (15.8%) and included hypertension (2 of 38 patients [5.3%]), increased alanine aminotransferase level (1 [2.6%]), anal fistula (1 [2.6%]), myocardial infarction (1 [2.6%]), and vascular disorders (1 [2.6%]). This evidence concerns the gene GPT and Anal fistula.